FDA Greenlights New Ozempic Indication: What It Means for Patients
The agency expanded approval for semaglutide this month. Here is what changes for prescribers, insurers, and the people who actually take it.
A semaglutide injection pen resting on a clinic countertop in soft window light.
For nearly a decade, semaglutide has lived a double life — quietly prescribed for type 2 diabetes, loudly discussed for weight loss. This month's expanded FDA indication finally aligns the label with how the drug is actually used.
What changed, in plain language
The agency broadened approval to cover adults with elevated cardiovascular risk regardless of diabetes status. In practice, that means a primary-care physician can now prescribe semaglutide to a patient whose risk factors — hypertension, prior cardiac event, family history — would previously have required an off-label justification.
The clinical evidence has been building toward this for years. The SELECT trial, published in 2023, reported a 20% reduction in major adverse cardiovascular events among non-diabetic adults with obesity. Subsequent analyses have held up.
Why insurers care
The new indication does not automatically unlock coverage. Most commercial plans still require step therapy, and Medicare's coverage of anti-obesity medications remains restricted by statute. But payers tend to follow the label, and a broader indication makes prior authorization harder to deny when cardiovascular risk is documented.
A label change does not change biology. It changes paperwork. That alone moves a lot of patients.
What patients should ask
If you already take semaglutide for diabetes, nothing about your prescription changes. If you have been declined coverage and your cardiovascular risk profile is significant, it is worth a conversation with your physician about resubmitting under the new indication.
- Bring documentation of risk factors to the appointment
- Ask whether your dose schedule should change
- Confirm pharmacy availability — supply remains uneven in many regions
The bigger question is what this means for the next wave of GLP-1 medications already in late-stage trials. We will keep covering it.
